Navigation Links
PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
Date:9/23/2013

London (PRWEB) September 23, 2013

PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients’ survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems

The UK has the second lowest prevalence of CML, and is currently the smallest CML market of the 7MM. Although an increasing prevalence of CML and the launch of Bosulif and Iclusig will act as driving forces of market growth, it will not be enough to compensate for erosion of Gleevec and Sprycel sales once their generic equivalents hit the market.

Scope

-Overview of the CML including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in the UK from 2012-2022.
-Analysis of the impact of key events as well the drivers and restraints affecting the UK CML market.

Reasons to buy

-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for CML
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of drug performance
-Obtain sales forecast for drugs from 2012-2022 in the UK

Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Clinical Staging 14
3.1.4 Prognosis 15
3.1.5 Quality of Life 16
3.2 Symptoms 16
4 Disease Management 18
4.1 Global Trends 18
4.1.1 Treatment Overview 18
4.1.2 Diagnostic Tests 20
4.1.3 Genetic Testing 21
4.1.4 Monitoring Patient Response to Treatment 23
4.1.5 Future Directions: Discontinuation Therapy 26
4.2 UK 27
4.2.1 Diagnosis and Monitoring 27
4.2.2 Clinical Treatment 27
4.2.3 Genetic Testing 29
5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor Assessment 30
5.3 Product Profiles- Major Brands 33
5.3.1 Gleevec (imatinib) 33
5.3.2 Sprycel (dasatinib) 37
5.3.3 Tasigna (nilotinib) 43
5.3.4 Bosulif (bosutinib) 48
5.3.5 Iclusig (ponatinib) 53
5.3.6 Minor Therapeutic Classes 57
6 Opportunity and Unmet Need 59
6.1 Overview 59
6.2 Unmet Need: A Drug that Can Cure CML 60
6.3 Unmet Need: Lower Annual Cost of Therapy 61
6.4 Unmet Need: Treatments for Patients Who Have Primary Resistance to or are Refractory to TKIs 62
6.5 Unmet Need: More Efficacious Treatments for AP and BP CML 62
6.6 Unmet Need: Therapies with Fewer Chronic Side Effects 63
6.7 Unmet Need: Better Compliance from Patients on Long-Term Oral Therapy 63
6.8 Unmet Need: Methods of Determining the Optimal Therapy for a Patient 64
6.9 Opportunity: Exploration into Discontinuation Therapy 64
6.10 Opportunity: Companion Devices to Enhance Patient Adherence to Oral Therapy 65
6.11 Opportunity: Therapies with BCR-ABL Independent MOAs 65
6.12 Opportunity: Extended-Release Formulations of TKIs 66
6.13 Opportunity: Biomarkers to Identify the Optimal Therapy for a Given Patient 66
7 Pipeline Assessment 67
7.1 Overview 67
7.2 Innovative Early-Stage Approaches 67
7.2.1 Project 1: The Wnt Signaling Pathway 69
7.2.2 Project 2: Jak2 Inhibitors 70
7.2.3 Project 3: Grb-2 71
7.2.4 Case Study: Smoothened Inhibitors 72
8 Market Outlook 73
8.1 UK 73
8.1.1 Forecast 75
8.1.2 Key Events 76
8.1.3 Drivers and Barriers 76
9 Appendix 79
9.1 Bibliography 79
9.2 Abbreviations 85
9.3 Methodology 88
9.4 Forecasting Methodology 88
9.4.1 Diagnosed CML patients 88
9.4.2 Drug-treated Patients on X Line of Therapy 89
9.4.3 Drugs Included in Each Therapeutic Class 89
9.4.4 Launch and Patent Expiry Dates 89
9.4.5 General Pricing Assumptions 90
9.4.6 Compliance Assumptions for Oral TKIs 90
9.4.7 Individual Drug Assumptions 91
9.4.8 Generic Erosion 93
9.4.9 Pricing of New Market Entrants 93
9.5 Physicians and Specialists Included in this Study 94
9.6 Survey of High Prescribing Physicians 95
9.7 About the Authors 96
9.7.1 Authors 96
9.7.2 Epidemiologists 97
9.7.3 Global Director of Epidemiology and Clinical Trials Analysis 98
9.7.4 Global Head of Healthcare 99
9.8 About GlobalData 100
9.9 Contact Us 100
9.10 Disclaimer 100

List of Tables

Table 1: The Staging of CML as Defined by Commonly Used Staging Systems 14
Table 2: Prognostic Scoring Systems for CML 15
Table 3: Common Symptoms of CML by Disease Phase 17
Table 4: Most Commonly Followed Treatment Guidelines for CML 19
Table 5: Most Prescribed First-Line Therapies for CP, AP and BP CML in the Global Markets, 2013 20
Table 6: Suggested Treatments for CML Patients with Selected BCR-ABL Kinase Domain Mutations 23
Table 7: CML Response Types, Criteria, and Corresponding Tests 24
Table 8: Leading Treatments for Chronic Myeloid Leukemia, 2013 32
Table 9: Product Profile – Gleevec 34
Table 10: Hematologic and Cytogenetic Reponses to Gleevec in Newly Diagnosed CML Patients 35
Table 11: Gleevec SWOT Analysis, 2013 37
Table 12: Product Profile – Sprycel 39
Table 13: Hematologic and Cytogenetic Reponses to Sprycel in Imatinib Resistant or Intolerant Advanced Phase CML 40
Table 14: Sprycel SWOT Analysis, 2013 42
Table 15: Product Profile – Tasigna 44
Table 16: Molecular and Cytogenetic Responses of Tasigna Compared with Gleevec in Newly Diagnosed Ph+ CML in CP 45
Table 17: Tasigna SWOT Analysis, 2013 47
Table 18: Product Profile – Bosulif 49
Table 19: Bosulif SWOT Analysis, 2013 52
Table 20: Product Profile – Iclusig 54
Table 21: Iclusig SWOT Analysis, 2013 57
Table 22: Summary of Minor Therapeutic Classes, 2013 58
Table 23: Overall Unmet Needs – Current Level of Attainment 60
Table 24: Early-stage Pipeline Projects in CML 68
Table 25: Sales Forecasts ($m) for CML Therapeutics in the United Kingdom, 2012–2022 75
Table 26: Key Events Impacting Sales of CML Therapeutics in the UK, 2013 76
Table 27: CML Market in the UK – Drivers and Barriers, 2013 76
Table 28: Key Launch Dates 89
Table 29: Key Patent Expiries 89
Table 30: Physicians Surveyed, by Country 95

List of Figures

Figure 1: Translocation of Chromosomes 9 and 22 12
Figure 2: Comparison of Normal and Leukemia Blood Cells 13
Figure 3: Sales for CML Therapeutics in the UK by Brand, 2012–2022 75

Read the full report:

PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_chronic_myeloid_leukemia_cml_united_kingdom_drug_forecast_market_analysis_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reporbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com

Read the full story at http://www.prweb.com/releases/2013/9/prweb11150480.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players
2. PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022
3. PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - US Drug Forecast and Market Analysis to 2022
4. Chronic aggressive behavior in boys: Epigenetic sources?
5. Rosacea Control by Forces of Nature Offers Brand-New Solution to Treat Chronic Skin Condition
6. CWRU researchers find what stresses parents with a chronically ill child
7. Predicting who will have chronic pain
8. Treatment Rates of Prevalent Chronic Conditions Are Low in Brazil, According to Kantar Health Research
9. Chronic Kidney Disease Market: 81M CKD Cases by 2022 Says a New Research Report at ReportsnReports.com
10. Chronic Fatigue Treatment
11. How “End Tiredness Program” Helps People Get Rid Of Tiredness – Vinamy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare ... suppliers for its inaugural Member Conference at the Paris Hotel in Las Vegas, ... operational health of America’s healthcare providers. , The conference was highlighted by the ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... one that has a significant negative impact on long-term patient survival, reports a ... The results, published online this week in the Journal of Thoracic and Cardiovascular ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising health care ... of Sun Health Senior Living (SHSL) may not share those same worries ... prescription copays for the year, while holding the line on increasing their contributions, including ...
(Date:5/26/2016)... ... , ... The Lung Institute has partnered with the Gulfcoast North ... 6 at their clinic in downtown Tampa. The class is complimentary for the public. ... created a free downloadable 4 Week Smoking Cessation Guide for those who ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eugene Batelli, D.P.M., ... with his wonderful accolades and stellar patient reviews, Dr. Batelli continues to be ... Dr. Eugene Batelli is a highly trained Podiatric Surgeon who specializes in treating ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... Digital Health Dialog, LLC dba EngagedMedia ... US Patent and Trademark Office of U.S. Patent ... for electronic opt-­in and processing of discount coupons ... compliance and otherwise. Logo - http://photos.prnewswire.com/prnh/20160524/371583LOGO ... "Our technology allows for individuals to opt­-in to ...
(Date:5/24/2016)... 2016 Cirujanos holandeses han puesto ... los médicos a compartir sus mejores prácticas por el ... Profesionales médicos de Europa, África, Asia ... la aplicación, que combina la transmisión en vivo con ... Educación   "Imagine un médico de ...
(Date:5/24/2016)... , May 24, 2016  NxStage Medical, Inc. ... company focused on advancing renal care, today announced that ... to participate in the following schedule of investor conferences. ... made available at http://ir.nxstage.com/ .   ... Jefferies Healthcare Conference NY, NY           Friday, June 10, ...
Breaking Medicine Technology: